Literature DB >> 12424722

Risk factors for invasive aspergillosis in liver transplant recipients.

Jesús Fortún1, Pilar Martín-Dávila, Santiago Moreno, Emilio De Vicente, Javier Nuño, Angel Candelas, Rafael Bárcena, Miguel García.   

Abstract

Aspergillosis is a potential, severe, and usually early complication of liver transplantation. New promising strategies, such as detecting Aspergillus antigenemia, have been used for the diagnosis of aspergillosis in immunosuppressed patients, but the impact in solid organ transplantation is not well known. A case-control study in 260 adults who underwent liver transplantation from January 1994 to June 2000 was performed. A case was defined as any liver transplant recipient with a proven or probable diagnosis of invasive aspergillosis. Controls were defined as a liver transplant recipient without aspergillosis infection with a survival longer than two months after transplantation. Clinical and analytical variables, including Aspergillus antigenemia, were compared. A special analysis was performed in patients in whom late aspergillosis developed (after day 100 posttransplantation). Among 260 patients, invasive aspergillosis developed in 15 (5.6%). Median time from transplantation to aspergillosis in 13 patients with sufficient data for analysis was 126 days (range, 22 to 1117). Seven (54%) developed the infection after day 100 posttransplantation. Thirty-eight patients were used as controls. Antigenemia was available in nine of 13 cases and in 33 of 38 controls. By multivariate analysis, retransplantation (OR, 29.9 [95% CI, 2.1 to 425.1]), dialysis requirements after transplantation (OR, 24.5 [95% CI, 1.25 to 354]), and the presence of Aspergillus antigenemia in serum at any time point after transplantation (OR, 50.0 [95% CI, 3.56 to 650]) were independently associated to aspergillosis. In the subgroup of patients that developed late aspergillosis, cytomegalovirus infection (OR, 6.7 [95% CI, 1.0 to 42.5]) was the only independent factor associated. Hepatic and renal dysfunction predispose to Aspergillus infection in liver transplant recipients. Cytomegalovirus infection and increased immunosuppression favor invasive aspergillosis during the late posttransplantation period. Aspergillus antigenemia seems to be a good predictor of invasive aspergillosis.

Entities:  

Mesh:

Year:  2002        PMID: 12424722     DOI: 10.1053/jlts.2002.36239

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  16 in total

1.  Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.

Authors:  J W Hiemenz; I I Raad; J A Maertens; R Y Hachem; A J Saah; C A Sable; J A Chodakewitz; M E Severino; P Saddier; R S Berman; D M Ryan; M J Dinubile; T F Patterson; D W Denning; T J Walsh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-12       Impact factor: 3.267

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children.

Authors:  Brian T Fisher
Journal:  Curr Fungal Infect Rep       Date:  2013-03-01

Review 4.  Infections after orthotopic liver transplantation.

Authors:  Mark Pedersen; Anil Seetharam
Journal:  J Clin Exp Hepatol       Date:  2014-07-24

Review 5.  Current understanding of HOG-MAPK pathway in Aspergillus fumigatus.

Authors:  Dongmei Ma; Ruoyu Li
Journal:  Mycopathologia       Date:  2012-11-18       Impact factor: 2.574

6.  [Caspofungin after solid organ transplantation in Germany: observational study on treatment of invasive fungal infections].

Authors:  C Lichtenstern; J Pratschke; U Schulz; M Schmoeckel; W Knitsch; P Kaskel; K J Krobot; M A Weigand; M Winkler
Journal:  Anaesthesist       Date:  2010-11-12       Impact factor: 1.041

Review 7.  Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection.

Authors:  Judith A Anesi; John W Baddley
Journal:  Infect Dis Clin North Am       Date:  2015-12-28       Impact factor: 5.982

8.  Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum.

Authors:  Nina Singh; Asia Obman; Shahid Husain; Sherrie Aspinall; Sue Mietzner; Janet E Stout
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 9.  Patients at high risk of invasive fungal infections: when and how to treat.

Authors:  Maria J G T Rüping; Jörg J Vehreschild; Oliver A Cornely
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Invasive fungal infections in solid organ transplant recipients.

Authors:  Shmuel Shoham; Kieren A Marr
Journal:  Future Microbiol       Date:  2012-05       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.